Prospects for NK Cell Therapy of Sarcoma
Department of Clinical Immunology, Doctoral School, Medical University of Warsaw, 02-006 Warsaw, Poland
Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, 0310 Oslo, Norway
Department of Immunology, Medical University of Warsaw, 02-097 Warsaw, Poland
Department of Oncology, Oslo University Hospital, 0310 Oslo, Norway
Department of Clinical Immunology, Medical University of Warsaw, 02-006 Warsaw, Poland
Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, 141 86 Stockholm, Sweden
Authors to whom correspondence should be addressed.
Received: 15 November 2020 / Revised: 8 December 2020 / Accepted: 9 December 2020 / Published: 11 December 2020
Sarcomas are a group of aggressive tumors originating from mesenchymal tissues. Patients with advanced disease have poor prognosis due to the ineffectiveness of current treatment protocols. A subset of lymphocytes called natural killer (NK) cells is capable of effective surveillance and clearance of sarcomas, constituting a promising tool for immunotherapeutic treatment. However, sarcomas can cause impairment in NK cell function, associated with enhanced tumor growth and dissemination. In this review, we discuss the molecular mechanisms of sarcoma-mediated suppression of NK cells and their implications for the design of novel NK cell-based immunotherapies against sarcoma.